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Background
Bone is a dynamic tissue, undergoing continuous remodeling in order to fulfill the
metabolic and mechanical demands of the body. Two cell types, osteoblasts (bone
forming cells) and osteoclasts (bone resorbing cells), are primarily responsible for
remodeling the skeleton. Critical to the integrity of the skeleton, the formative and
resorptive activities of these two bone cells must be spatiotemporally linked (or coupled)
at local sites of bone turnover throughout the skeletal life cycle. Any disease process that
uncouples the activities of osteoclasts and osteoblasts will disrupt the delicate balance
between bone formation and resorption and produce an osteoporotic phenotype
characterized by an increase in bone fragility and risk of fracture.
Four stages compose the normal bone remodeling cycle: activation, resorption,
reversal, and formation (reviewed in Raisz, 1999). The initial activation stage is
characterized by the differentiation, migration, and fusion of the large multinucleated
osteoclasts. As the activated osteoclasts enter the resorption stage, these cells attach to
mineralized bone and seal off a section of the bony surface. The osteoclasts then begin to
secrete hydrogen ions and low pH-resistant lysosomal enzymes into the sealed resorption
compartment. The combined effects of a localized acidic environment and proteolytic
enzymes produce irregularly scalloped cavities on the trabecular bone surface referred to
as Howship’s lacunae. The reversal stage of the bone remodeling cycle follows the
resorption stage and is distinguished by the recruitment of preosteoblasts to the newly-
formed Howship’s lacunae. As the preosteoblasts accumulate within the resorption
lacunae, the bone remodeling cycle enters theformation stage, during which the
preosteoblasts differentiate into mature osteoblasts and begin to secrete bone matrix
proteins. Subsequently, as the uncalcified bone matrix mineralizes, the integrity of the
bone at the site of remodeling is restored, and the bone remodeling cycle is complete.
As discussed above, precise spatiotemporal coupling of osteoblastic activity to
that of osteoclasts during the reversal stage prevents the loss of skeletal integrity.
Multiple growth factors, hormones, and cytokines have been implicated as potential
coupling factors (Raisz, 1999). Several investigators (Brown et al., 1996;Brown et al.,
1995;Godwin & Soltoff, 1997;Sugimoto et al., 1993;Yamaguchi et al., 1998) have
hypothesized that extracellular calcium, a divalent cation, may serve as a coupling factor.
This hypothesis is based on the observations that [ 1 ] within the Howship’s lacunae,
extracellular calcium (Cae) can reach a concentration of 40 mM as a result of osteoclastic
bone resorption (Silver et al., 1988), and [2] elevated Cae stimulates proliferation
(Quarles et al., 1991 ;Sugimoto et al., 1994;Yamaguchi et al., 1998) and chemotaxis
(Godwin & Soltoff, 1997;Sugimoto et al., 1993) of osteoblasts in vitro.
Kanatani et al. (1991) provided some of the first evidence demonstrating that an
increase in Cae acts as an osteoblast mitogen. They found that Cae (3-20 mM) stimulated
mitogenesis of MC3T3-E1 osteoblasts in a concentration-dependem manner. A
statistically significant increase in [3H]thymidine incorporation was observed at a
concentration of 3 mM, at 4 mM an increase of over 3 fold was demonstrated, and the
effects plateaued at almost 4 fold with Cae concentrations between 5-20 mM (Kanatani et
aL, 1991). In support of these findings, Quarles et aL (1994) demonstrated a 500%
increase in mitogenic activity (DNA synthesis) of MC3T3-E1 osteoblasts when exposed
to elevated Cae. Yamaguchi et al. (1998) also provided supportive evidence showing
increases in MC3T3-E1 osteoblastic mitogenesis of25% and 75% at Cae concentrations
of 2.8 mM and 4.8 mM, respectively.
Elevated levels of Cae have also been shown to stimulate chemotaxis of MC3T3-
E 1 osteoblasts. Sugimoto et al. (1993) discovered that 5 and 8 fold increases in
chemotaxis were associated with Cae concentrations of 3 mM and 5 mM, respectively.
They found that the chemotactic effects of Cae plateaued at a 25 fold increase when the
osteoblasts were exposed to Cae concentrations of 10 mM (Sugimoto et al., 1993).
Subsequently, Godwin and Soltoff (1997) observed concentration-dependent increases in
chemotaxis of MC3T3-E1 osteoblasts between 1.8 and 5 mM extracellular calcium.
These investigators reported the peak increase in chemotactic effect was 7.9 fold,
occurring at 5 mM Cae (Godwin & Soltoff, 1997). Lastly, Yamaguchi et al. (1998)
showed that exposure of MC3T3-E cells to high Cae concentrations (up to 4.8 mM)
stimulated chemotaxis up to 200% compared to the control. This information suggests
that a CaR in osteoblasts could play a key role in regulating bone tumover by stimulating
the proliferation and migration of such cells to sites of bone resorption as a result of local
release of Cae.
While these studies provide strong evidence that elevated Cae may act as a
recruiting agent for osteoblasts, the mechanism by which osteoblasts sense and respond
to alterations in extracellular calcium concentration remains unresolved. The mechanism
may be similar to that found in parathyroid cells. These cells detect Cae via a 120 kDa
calcium-sensing receptor (CAR) belonging to the G-protein-coupled seven-
transmembrane superfamily of receptors (Brown et al., 1993). Brown et al. (1993)
initially cloned this CaR from bovine parathyroid cells and demonstrated that parathyroid
hormone secretion was suppressed upon activation of the CaR. Subsequently,
homologous forms of the parathyroid cell CaR have been found in a variety of cell types,
including human parathyroid, kidney, thyroid, fibroblasts and brain cells (Brown et al.,
1993;Garrett et al., 1995;McNeil et al., 1998;Riccardi et al., 1995;Ruat et al., 1995). In
addition to the divalent cation calcium, agonists for the CaR include the trivalent cation
gadolinium (Gd3+) and the polyvalent cation neomycin (Brown et aL, 1993).
It is still unclear whether osteoblasts utilize a parathyroid cell CaR homolog to
mediate the mitogenic and chemotactic effects of elevated calcium. Using
oligonucleotide primers generated from the DNA sequence of the partially cloned
extracellular domain of the mouse AtT-20 pituitary cell CaR gene and reverse
transcription-polymerase chain reaction (RT-PCR), Yamaguchi et al. (1998)
demonstrated that MC3T3-E 1 osteoblasts produce a 319 bp RT-PCR product which is the
expected size for a CaR-derived product. DNA sequence analysis of the 319 bp PCR
products revealed a 100% sequence identity with the mouse AtT-20 cell CaR sequence
which is homologous to a glycosylated human CaR, bovine parathyroid CaR, and mouse
kidney CaR. To detect the protein expression of the parathyroid cell CaR in MC3T3-E1
cells, Western blot analysis and immunocytochemistry were performed using a CaR-
specific polyclonal antiserum (4637) raised against a peptide (FF-7) corresponding to
amino acids 345-359 of the bovine parathyroid cell CaR (Yamaguchi et al., 1998).
Immunocytochemistry revealed strong CaR staining which was eliminated by
preincubating the primary antiserum with the peptide against which it was raised.
Western analysis with the 4637 antibody revealed the presence of homologous
parathyroid cell CaR protein in MC3T3-E 1 osteoblast lysates (Yamaguchi et al., 1998).
Despite these findings, controversy remains as to the exact identity of the
osteoblast CaR. Quarles et al. (1997) were unable to detect CaR expression in MC3T3-
E1 osteoblasts by RT-PCR, Northem analysis, or Westem blot analysis. RT-PCR was
performed using RNA from MC3T3-E 1 osteoblasts and intron-spanning oligonucleotide
primers capable of amplifying murine CaR from mouse kidney RNA. While the kidney
CaR primers successfully amplified the predicted 940 bp product from RNA extracted
from murine kidney, a similar RT-PCR product could not be amplified from MC3T3-E 1
osteoblasts total RNA (Quarles et al., 1997). In addition to RT-PCR, Northern blot
analyses were performed using poly(A)+ RNA derived from MC3T3-E1 osteoblasts, a
497 bp murine mouse kidney CaR DNA probe, and additionally with N-terminal cDNA
probes from bovine and human CaR (Quarles et al., 1997). Although the CaR probe
recognized the predicted 7.0 and 4.0 kb transcripts in the rat and mouse kidney,
homologous CaR mRNA was not detected in the MC3T3-E1 osteoblasts.
To affirm the Northern results, Pi et al. (1999) performed Westem blot analyses
using a highly specific monoclonal antibody to parathyroid cell CaR (ADD). The ADD
antibody was generated from a synthetic peptide derived of a region that is 100%
conserved between the human, rat, and mouse CaR. The mouse neuronal cell line AtT-
20, which is known to express a functional CaR, was used as a positive control for the
Western blot analysis. While the ADD antibody detected bands of140 and 165 kDa in
membrane protein preparations from the mouse AtT-20 cells, it failed to detect
homologous CaR from MC3T3-E1 osteoblasts. Based on these findings, Quarles et al.
(1997) and Pi et al. (2000,1999) argue that osteoblasts do not use a parathyroid cell CaR
homolog to mediate the physiological effects of elevated Cae.
While the exact identity of the Cae-sensing receptor in osteoblasts remains
controversial, recent strides have been made in understanding the signaling mechanism
underlying Cae-regulated physiology. Godwin and Soltoff (1997) have presented
evidence suggesting that elevated Cae stimulates chemotaxis of MC3T3-E1 osteoblasts
via a G-protein-linked receptor. Pertussis toxin, an inhibitor ofthe Gi-isoform of
heterotrimeric G-proteins, reduced Cae-stimulated chemotaxis of the osteoblasts by over
90% (Godwin & Soltoff, 1997). These investigators also found that the phospholipase C
inhibitor U73122 blocked calcium-induced chemotaxis by 88%, suggesting that the
osteoblast CaR is coupled to Gq as well as Gi. Interestingly, down-regulation of protein
kinase C did not interfere with Cae-stimulated chemotaxis. Thus, chemotaxis stimulated
by Cae does not appear to require protein kinase C activation (Godwin & Soltoff, 1997).
Preliminary data suggests that, similar to chemotaxis, Cae-stimulated mitogenesis
of osteoblasts is mediated via a G-protein-coupled CaR. The Gi-protein inhibitor
pertussis toxin inhibited Cae-induced [3H]Thymidine incorporation by 98%, suggesting
that the osteoblast CaR utilizes Gi-protein to transduce its mitogenic signal (unpublished
data, Godwin). Forskolin, an adenylyl cyclase activator, blocked Cae-induced DNA
synthesis by 63%, suggesting that CaR-mediated regulation of osteoblast mitogenesis
requires Gi-protein-dependent inhibition of adenylyl cyclase and its downstream effector
protein kinase A. U73122, an inhibitor of the signaling molecule phospholipase C (PLC),
blocked Cae-induced [3H]thymidine incorporation by 56%. These results are consistent
with the observation that the CaR activates PLC (unpublished data, Godwin). In contrast
to chemotaxis, Cae-stimulated mitogenesis of osteoblasts was reduced by 53% upon
protein kinase C down-regulation. Finally, Godwin and Soltoff examined the role of
extracellular signal-regulated kinase (ERK1/2) in CaR-mediated osteoblast mitogenesis.
In the presence of the ERK1/2 cascade inhibitor PD90859, they found that Cae-promoted
[3H]thymidine incorporation was reduced by 61% in MC3T3-E 1 osteoblasts (unpublished
results, Godwin), suggesting that ERK1/2 plays a critical role in CaR-stimulated
osteoblast proliferation. The overallpurpose ofthis project is to define the signaling
mechanisms by which elevated extracellular calcium activates ERK1/2 in osteoblasts.
ERK1/2 is a member of the mitogen-activated protein kinase (MAP kinase)
family of signaling enzymes. Two other major subfamilies ofMAP kinase-related
enzymes have been identified: stress-activated protein kinase (SAPK) and p38. SAPK
and p38 are activated by conditions of stress including UV irradiation and
hyperosmolarity, and are poorly induced by growth stimulants (reviewed in Treisman,
1996). In fact, several SAPK targets may be important negative regulators of cell
growth. ERK1/2, on the other hand, are generally responsible for transducing a growth-
positive signal. ERK1 (44 kDa) and ERK2 (42 kDa) are derived from two separate genes
and are 90% similar in protein sequence. ERK1/2 can be activated by both receptor
tyrosine kinases and G-protein-coupled receptors. Downstream of the receptors, the well-
established signaling cascade ras -> raf-> MEK -> ERK1/2 has been defined as the
primary mechanism for ERK1/2 activation (Guan, 1994;Su & Karin, 1996). Upon
activation, ERK1/2 translocates from the cytoplasm into the cell nucleus where it serves
as a serine/threonine kinase to phosphorylate specific transcription factors (Davis, 1995).
Transcription factors Ilk-I/p62vcv, c-Myc, C/EBP[3, c-Fos, and serum response factor
(SRF) have been shown to be phosphorylated by ERK1/2 (Gille et al., 1992;Nakajima et
al., 1993 ;Seth et al., 1992). The phosphorylated transcription factors regulate the
expression of a wide array of growth-specific genes by binding to transcription elements,
including serum-response elements (SRE), within the genome.
Hypothesis
The heterotrimeric G-protein Gi, protein kinase C, and protein kinase A play a
role in regulating osteoblast calcium-sensing receptor-mediated activation of ERK1/2.
Objectives
1. To determine which heterotrimeric G-protein isoform is involved in calcium
receptor-mediated activation of ERK1/2 in osteoblasts.
2. To determine whether calcium receptor-mediated activation of ERK1/2 is PKC-
dependem.
3. To determine whether protein kinase A plays a role in calcium-receptor mediated
activation of ERK1/2 in osteoblasts.
Research Plan
Several growth factors have been implicated as potential coupling agems linking
bone resorption to bone formation at local sites of bone remodeling (Parfitt, 1987). The
divalent cation calcium may act as coupling factor given its mitogenic and chemotactic
properties for osteoblasts. Preliminary data indicate that the osteoblasts detect alterations
in extracellular calcium via a G-protein-coupled calcium-sensing receptor. Furthermore,
evidence suggests that extracellular signal-regulated kinase (ERK1/2), a member of the
mitogen-activated protein kinase superfamily, plays a role in mediating the proliferative
effect of elevated calcium in osteoblasts. The short-term objective of this project was to
examine the signaling mechanism by which elevated extracellular calcium activates
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ERK1/2 in osteoblasts. The general hypothesis supporting this short-term goal proposes
that the heterotrimeric G-proteins G_i and G, protein kinase C, and protein kinase A play
a role in regulating osteoblast calcium-sensing receptor-mediated activation of ERK1/2.
Specific Aim #1. To determine which heterotrimeric G-protein isoform(s) is(are) involved
in calcium receptor-mediated activation of ERK1/2 in osteoblasts.
Hypothesis." The heterotrimeric G-protein isoform G and is involved in the
regulation ofCaR-mediated activation ofERK1/2.
To determine whether the heterotrimeric G-protein isoform Gi plays a role in
calcium receptor-mediated activation of p42/44 MAP kinase, MC3T3-E1 osteoblasts
were pretreated with vehicle alone or pertussis toxin (a Gi-protein inhibitor). The cells
were then stimulated for 0 to 10 min with serum-free media alone (1.8 mM calcium),
elevated extracellular calcium (3 mM-10 mM total), or PDGF-BB (10 ng/ml). We
performed Westem Blot analyses using phospho-specific anti-ERK1/2 antibodies (New
England Biolabs) specific for the doubly-phosphorylated active form of this signaling
enzyme (see METHODS-Protocol for Western Blot Analysis of Activated ERKI/2).
Potential pitfalls of the experiment related to the specificity of the G-protein
chemical inhibitor. Measuring PDGF-stimulated activation of ERK1/2 in cells treated
with these inhibitors aided in determining whether a non-specific effect was present.
Therefore, if PDGF-stimulated ERK1/2 activation is affected by the G-protein inhibitor,
then a non-specific inhibition or even cell death may be taking place and not specific G-
protein inhibition.
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Specific Aim #2. To determine whether calcium receptor-mediated activation of ERK1/2
is PKC-dependent.
Hypothesis." Protein kinase C (PKC) is involved in CaR-mediated activation of
ERK1/2.
To determine whether calcium receptor-mediated activation of the MAP kinase
cascade is protein kinase C-dependent, MC3T3-E 1 osteoblasts were pretreated with
vehicle alone, 100 nM GF109203X or 500nM and 1000nM Go6983 (protein kinase C
inhibitors), or prolonged exposure to 1 laM phorbol ester (to downregulate protein kinase
C). The cells were then stimulated for 0 to 10 min with serum-free media alone (1.8 mM
calcium), elevated extracellular calcium (3 mM-10 mM total), or PDGF-BB (10 ng/ml).
Western Blot Analyses using antibodies specific for the activated form ofERK1/2 were
used to examine the role ofPKC in CaR-mediated activation ofMAP kinase (see
METHODS-Protocol for Western Blot Analysis of Activated ERKl/2).
Potential pitfalls of the experiment related to the specificity of the protein kinase
C chemical inhibitors. By using several different protein kinase C inhibitors and
measuring ERK1/2 activation via the PMA-dependant PKC pathway as a positive
control, it could be determined if the PKC inhibitors were affecting Cae-stimulated
ERK1/2 activation via this same pathway or by another.
Specific Aim #3. To determine whether protein kinase A plays a role in calcium-receptor
mediated activation of ERK1/2 in osteoblasts.
Hypothesis." Activated Protein Kinase A (PKA) inhibits CaR-mediated ERK1/2
activity.
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Protein kinase A is the downstream effector of G-protein-mediated alterations in
cAMP concentration. PICA, acting as a serine/threonine kinase, phosphorylates target
proteins containing the consensus sequence Arg-Arg-X-Ser/Thr-X (Meinkoth et al.,
1993). Target proteins ofPKA include the transcription factor CREB and $6 ribosomal
protein (Meinkoth et al., 1993 ;Walsh & Van Patten, 1994).
To determine whether calcium receptor-mediated activation of the MAP kinase
cascade is protein kinase A-dependent, MC3T3-E1 osteoblasts were pretreated with
vehicle alone, 100 nM (PKI) myristoylated protein kinase inhibitor (14-22) amide, or 10
laM forskolin (adenylate cyclase activator). The cells were then stimulated for 5 min with
serum-free media alone (1.8 mM calcium), elevated extracellular calcium (3 mM-10 mM
total), or PDGF-BB (10 ng/ml). Western blot analyses using antibodies specific for the
activated form of ERK1/2 were also used to examine the role ofPKA in CaR-mediated
activation ofMAP kinase (see METHODS-Protocol for Western Blot Analysis of Activated ERKI/2).
Potential pitfalls of the experiment related to the specificity of the protein kinase A
chemical inhibitors. By using several different protein kinase A inhibitors and measuring
ERK1/2 activation via the PMA-dependant PKC pathway, it could be determined if the
PKA inhibitors were exhibiting a non-specific affect or if they were potentially affecting
only the PKA pathway.
Materials and Methods
Reagents
All chemicals were reagent grade or better, a-modified Eagle’s medium (a-
MEM), fetal calf serum (FCS), penicillin/streptomycin, trypsin, amphotericin B
(Fungizone) and phorbol 12-myristate 13-acetate (PMA) was obtained from GibcoBRL
(Grand Lake, NY). Human recombinant PDGF-BB was acquired from Upstate
Biochemicals Inc. (Lake Placid, NY). Bisindolylmaleimide I (GF109203X), PP2, PP3,
dibutyryl cAMP, forskolin, H-89, Protein kinase A inhibitor 14-22 amide, GP-Antagonist
2A, Ro 31-8220, pertussis toxin and PD90859 was obtained from Calbiochem (San
Diego, CA).
Cell Culture
MC3T3-E1 cells (Kodama et al., 1981), a clonal line of immortalized neonatal
murine calvarial osteoblasts, were kindly provided by Dr. Peter Hauschka (The
Children’s Hospital, Boston, MA). The cells were grown in a 95% air-5% CO2
atmosphere in 100 mm diameter dishes containing a-MEM plus 10% FCS, 100 gg/ml
streptomycin, 100 IU/ml penicillin, and 0.025 gg/ml amphotericin B at 37C. All
experiments were conducted with cells at or near confluency. Where noted, serum-
starvation of the MC3T3-E1 cells was accomplished through exposure to low serum
media (c-MEM plus 0.1% FCS) 12 h prior to stimulation.
The concentrations of the signaling molecule inhibitors used in this study were
selected based on previously observed effects of these inhibitors on Cae-induced
physiology in the MC3T3-E1 cells. For example, overnight exposure to pertussis toxin at
a concentration of 100 ng/ml was sufficient to reduce Cae-stimulated chemotaxis of the
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osteoblasts by 90% (Godwin & Soltoff, 1997). In addition, a determination of the
toxicity of the inhibitors was performed by examining trypan blue uptake and cell growth
in MC3T3-E 1 cells exposed to various concentrations of the inhibitors. Protein kinase C
downregulated cells were generated by 12 h incubation of cells in low serum t-MEM
containing 1 M PMA. Gi-protein inhibition was accomplished by 12 h exposure to low
serum t-MEM containing 100 ng/ml pertussis toxin. Cells were used early in their
passage to avoid differentiation that accompanies long-term cell culture.
Alterations in the Extracellular Calcium Concentration
The cells were maintained in t-MEM, which has a Cae concentration of 1.8 mM.
Cae elevation was achieved by adding CaC12 to ct-MEM.
Protocol for Western Blot Analysis of Activated ERK1/2
Quiescent cultures of MC3T3-E 1 osteoblasts were treated directly with elevated
concentrations of extracellular calcium + specific inhibitors for designated times. The
cells were washed twice with 4 ml cold phosphate buffered saline (PBS) (137 mM NaC1,
15.7 mM NaH2PO4, 1.47 mM KH2PO4, 2.68 mM KC1, pH 7.4), and were lysed in 1 ml
lysis buffer (137 mM NaC1, 20 mM Tris, 1 mM MgC12, 0.2 mM vanadate, 10% Iv/v]
glycerol, 1% [v/v] Nonidet P-40 [NP-40], 1 mM phenylmethylsulfonyl fluoride, 4.5 mM
sodium pyrophosphate, 1 tg/ml leupeptin, 1 tg/ml pepstatin, 1 mM ZnC12, 48 mM NaF, 9
mM 13-glycerophosphate). The lysates were transferred to 1.5 ml microfuge tubes,
vortexed and centrifuged at 16,000 X g (IEC Micromax microcentrifuge). A fraction of
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the cleared supematants was collected, diluted with 2X sample buffer, boiled and used
without immunoprecipitation as lysates to examine MAP kinase activation.
The cleared lysates were subjected to electrophoresis on a sodium dodecyl sulfate
(SDS)-I 5% polyacrylamide separating gel with a 3% stacking gel. Proteins were
transferred to nitrocellulose filters (0.2 tm pore size), which were then blocked with TBS
(20 mM Tris, 137 mM NaC1 [pH 7.6])-2% BSA for 1 h. The filters were washed three
times in TBS-0.2% Tween 20 (TTBS).
To identify the active form ofp42/44 MAP kinase, we used an anti-phospho-
specific ERK1/2 antibody (1"1000, New England Biolab) in TTBS/5% milk. An anti-
ERK2 antibody (1" 1000, New England Biolabs) was used to identify total p42 MAP
kinase. The blots were washed three times in TTBS and then exposed to secondary
antibody (anti-mouse horseradish perioxidase or anti-rabbit horseradish perioxidase
[Boehringer-Mannheim]) at a 1"10,000 dilution in TTBS/1% BSA or TTBS/5% milk for
1 h. Filters were washed three times with TTBS and twice with TBS. Immunoreactive
proteins were visualized and quantified using a Storm Imager (Molecular Dynamics) by
enhanced chemiluminescence (Amersham). Radiographs of the blots were scanned into a
computer and Scion Image Software was used to quantify the images for analysis.
Values were presented as either a fold increase in the phosphorylation of a particular
signaling molecule over unstimulated cells or as percent inhibition of maximal Cae-
stimulated phosphorylation of a specific signaling molecule.
Statistics
A two tailed T-test analysis was performed on each set of data using the statistical
program in Microsoft Excel. Mean values of each of the different sets of experiments
were used to compare the data within each experiment to each of the controls and to each
other. All values with p<.05 were considered statistically significant.
Results
A. Cae-stimulated activation (phosphorylation) of ERK1/2 in MC3T3-E1 osteoblasts.
To examine the concentration-dependent effects of elevated Cae on ERK1/2
activation, Western blot analysis was performed on MC3T3-E1 osteoblasts using an anti-
activated ERK1/2 antibody (Figs. 1A and 1B). The anti-activated ERK1/2 antibody
(New England Biolabs, Beverly, MA) recognizes ERK1/2 that has been phosphorylated
at threonine (Thr183) and tyrosine (Tyr185) amino acids. These two phosphorylation
sites must be phosphorylated in order for the ERK1/2 to be activated. MC3T3-E1
osteoblasts were serum-starved overnight in a low-serum media containing a basal Cae
concentration of 1.8 mM. Cells were then exposed for 5 minutes to Cae concentrations
ranging from the control of 1.8 mM (low-serum media) up to 25 mM. Duplicates were
done within each of the 3 separate experiments, and the mean values of the 3 experiments
were used for statistical analyses. The control (1.8 mM) Cae concentration did not
significantly activate ERK1 or ERK2 (ERK1/2), 2 mM Cae was sufficient to significantly
(p>.05) stimulate phosphorylation ofERK1/2 approximately 4.6/5.8, respectively, times
more than the control (Fig. 1A). Phosphorylation ofERK1/2 continued to increase with
increasing Cae concentrations. While 3 mM Cae stimulated an 8.0/10.2 fold increase over
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the control, Cae concentrations of 5 mM, 10 mM, and 25 mM exhibited 11.7/16.5,
19.0/24.6, and 39.3/46.2 fold increases, respectively. All of these increases in
phosphorylation of ERK1/2 were significant (p values <.05). A Cae concentration of 10
mM appeared to elicit almost twice the ERK1/2 phosphorylation relative to 5 mM Cae.
ERK1/2 phosphorylation peaked at 25 mM. Blots were stripped and reprobed using anti-
ERK2 antibody to ensure equivalent levels of ERK. (Figures 1B, 1Ai, 1Aii, 1Bi, 1Bii)
A time course of Cae-induced ERK1/2 activation was also performed by Western
blot analysis using the anti-activated ERK1/2 antibody (Figs. 2A and 2B). MC3T3-E1
osteoblasts were serum-starved overnight in a low-serum media containing a basal Cae
concentration of 1.8 mM. Cells were then exposed for 0, 1, 3, 5, 10, or 30 minutes to
low-serum media containing a concentration of 5 mM Cae (Fig. 2A). Duplicates were
done within each of the 4 separate experiments, and the mean values of these experiments
were used for statistical analyses. At 1 min of exposure to 5 mM Cae, ERK1/2 activity
was slightly above controls (0.046/0.071), however, not significant (p=0.47/0.25). A
6.1/9.7 fold increase in ERK1/2 phosphorylation occurred by 3 minutes of exposure and
reached a maximum of 10.9/14.8 at 5 min. All of these increases were statistically
significant with p-values of less than 0.05. At 10 min, ERK1/2 phosphorylation had
decreased to just 5.7/8.6 times that of controls. While the 8.6 fold increase in ERK2
phosphorylation remained significant (p=0.003) the phosphorylation seen for ERK1 was
no longer significant (p=0.069). By 30 min, ERK1/2 phosphorylation was absent
revealing values lower than those of controls. The blots were stripped and reprobed
using anti-ERK2 antibody to ensure equivalent levels of ERK. (Figures 2B,2Ai, 2Aii,
2Bi, 2Bii)
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B. Role of Gi in Cae-stimulated ERK1/2 phosporylation
To determine if the Gi-protein is involved in Cae-stimulated ERK1/2 activation in
MC3T3-E1 osteoblasts, pertussis toxin (PTX) was used to inhibit its effects. MC3T3-E1
osteoblasts were serum-starved ovemight in a low-serum media containing a basal Cae
concentration of 1.8 mM. Gi was then inhibited in half of the cells by exposure to 101 of
100ng/ml PTX for 60 minutes. The remaining half of the cells were treated with vehicle
alone to use as controls. Of these two groups, one third from each group were used for
controls and nothing else was added, a second third from each group were treated for 5
minutes with 5mM Cae, and the last third were treated for 5 minutes with 100 nM PDGF-
BB for a positive control. Westem blot analyses were used to evaluate the activation of
ERK1/2 in the cells. Duplicates were done within each of the 3 experiments performed,
and the mean values of the experiments were used for statistical analyses. All cells
exposed to Cae and PDGF-BB showed significant (p<0.05) ERK1/2 activation. Cells
pre-treated with PTX showed no significant (p>0.05) inhibition ofERK1 or ERK2
activation. Pertussis toxin did not alter basal ERK1/2 activity. These results indicate that
Gi does not play a significant role in Cae-induced ERK1/2 activation, in MC3T3-E1
osteoblasts. (Figs. 3A&B, 4A&B)
C. Role ofPKC in Cae-stimulated ERK1/2 phosphorylation
To examine whether PKC, a downstream effector of PLC, contributes to Cae-
promoted activation of ERK1/2, MC3T3-E1 osteoblasts were serum-starved ovemight in
a low-serum media containing a basal Cae concentration of 1.8 mM. PKC was
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downregulated in half of the cells by ovemight exposure to 1 l.tM phorbol 12-myristate
13-acetate (PMA). The remaining half of the cells were exposed to vehicle (DMSO)
ovemight. Of these two groups, one third from each group were used for controls and
nothing else was added, a second third from each group were treated for 5 minutes with 5
mM CaC12, and the last third were treated for 5 minutes with 100 nM PMA. Westem blot
analyses were used to evaluate the activation of ERK1/2 in the cells. Duplicates were
done within each of the 4 experiments performed, and the mean values ofthe
experiments were used for statistical analyses. Those cells not exposed to PMA
ovemight and then treated with Cae or PMA for 5 minutes showed significant ERK1/2
phosphorylation (p<0.05, 7.1/13.5 ERK1 and 13.5/19.7 ERK2 fold increases) over basal.
However, when PKC was down-regulated by ovemight exposure to PMA, then treated
with PMA for 5 minutes, a significant (p<.05) decrease in ERK1/2 activation occurred.
Those cells treated with Cae for 5 minutes after overnight exposure to PMA exhibited a
significant (p<.05) reduction in ERK1 activation and a noticeable, but not statistically
significant, reduction in ERK2 activation This means that exposure to PMA ovemight
effectively down-regulates the PMA-dependant PKC pathway. Therefore, the reduction
in Cae stimulated ERK1/2 activation that can be observed after overnight exposure to
PMA is a result of the dependence of the Cae-stimulated ERK1/2 activation on the PMA-
dependant PKC pathway. These results indicate that Cae-induced ERK1/2 activation, in
MC3T3-E1 osteoblasts, is PKC-dependent. (Figs. 5A&B, 6A&B)
Go6983, a PKC inhibitor, was also used to block Cae-induced ERK1/2 activation
in another attempt to determine if PKC plays an important role in the ERK1/2 activation
cascade. MC3T3-E1 osteoblasts were serum-starved overnight in a low-serum media
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comaining a basal Cae concentration of 1.8 mM. One third of the cells were exposed to
500 nM Go6983 for 1 hour, 1/3 were exposed to 1000 nM Go6983 for 1 hour, and the
remaining third were exposed to vehicle (DMSO) and used as controls. After this, a
portion from each group were used for controls and nothing else was added, a second
group were treated for 5 minutes with 5 mM CaC12, and the remaining cells were treated
for 5 minutes with 100 nM PMA. Duplicates were done within each of the 5 experiments
performed and the mean values of the experiments were used for statistical analyses.
Westem blot analyses were used to evaluate the activation (phosphorylation) of ERK1/2
in the cells. All of the cells treated with Cae for 5 minutes, whether exposed to nothing,
500 nM or 1000 nM Go6983, showed significant (p<0.05) increases in ERK1/2
activation over controls and no significant decrease in ERK1/2 activation with either
concentration of Go6983 treatment. Those cells pretreated with either 500 nM or 1000
nM Go6983, then treated with PMA for 5 minutes showed a significant (p<.05) reduction
in ERK1/2 activation compared to cells exposed only to PMA for 5 minutes. These
results indicate that ERK1/2 activation via the PMA-dependant PKC pathway is
effectively inhibited by Go6983, but Cae-induced ERK1/2 activation is not and
consequently, is not solely dependent upon this pathway, if at all. (Figs. 7A&B, 8A&B)
GF 109203X, another PKC inhibitor, was also used to block Cae-induced ERK1/2
activation in another attempt to determine if PKC plays an important role in the ERK1/2
activation cascade. MC3T3-E1 osteoblasts were serum-starved overnight in a low-serum
media containing a basal Cae concentration of 1.8 mM. One half of the cells were
pretreated for 30 minutes with 1.25 tg/mL GF and the remaining half were exposed to
vehicle alone (DMSO) and used as controls. After this, a portion from each group were
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used for controls and nothing else was added, a second portion from each group were
treated for 5 minutes with 5 mM CaC12, and the remaining cells from each group were
treated for 5 minutes with 100 nM PMA. Duplicates were done within each ofthe 2
experiments performed and the mean values of the experiments were used for statistical
analyses. Westem blot analyses were used to evaluate the activation (phosphorylation) of
ERK1/2 in the cells. Those cells pretreated with GF then treated with 5mM Cae for 5
minutes showed a noticeable, yet statistically insignificant (p>.05), decrease in ERK1/2
activation compared to cells treated with 5mM Cae alone. GF did, however, significantly
(p<.05) inhibit ERK1/2 activation in those cells treated for 5 minutes with PMA. These
results indicate that ERK1/2 activation via the PMA-dependant PKC pathway is
effectively inhibited by GF, but Cae-induced ERK1/2 activation is not. Thus, Cae-
induced ERK1/2 activation does not appear to be strongly influenced by the PKC
pathway and PMA-induced ERK1/2 activation does. (Figs. 9A&B, 10A&B)
D. Role ofPKA in Cae-stimulated ERK1/2 phosphorylation
In the MC3T3-E1 cells, PKA activity appears to have an inhibitory effect on ERK1/2
activity stimulated by elevated Cae. To test how great this inhibitory effect is, MC3T3-
E 1 osteoblasts were serum-starved overnight in a low-serum media containing a basal
Cae concentration of 1.8 mM. PKA was then inhibited in half of the cells by exposure to
100 nM myristoylated protein kinase inhibitor (PKI) for 45 minutes. The remaining half
of the cells were left alone to use as controls. Of these two groups, one third from each
group were used for controls and nothing else was added, a second third from each group
were treated for 5 minutes with 5mM Cae, and the last third were treated for 5 minutes
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with 100nM PMA. Duplicates were used within each of the 3 experiments performed,
and the mean values of the experiments were used for statistical analyses. Western blot
analyses were used to evaluate the activation of ERK1/2 in the cells. All cells treated for
5 minutes with Cae or PMA showed significant (p<.05) activation of ERK1/2 over the
controls. Those cells pretreated with PKI for 45 minutes followed by a 5 minute
exposure to Cae or PMA did not show any significant decrease in ERK1/2 activation
compared to those cells treated for 5 minutes with only Cae or PMA. These results
indicate that any inhibitory effect that PKI may exhibit would not be due to non-specific
inhibition because it did not affect PMA-induced ERK1/2 activation and that Cae-
induced ERK1/2 activation in MC3T3-E1 osteoblasts may not be PKA-dependent. No
absolute results can be drawn, however, from these results due to the lack of proof that
PKI is actually working as it should, specifically, inhibiting the PKA pathway. In future
experiments, other agonists of ERK1/2 activation, in addition to PMA, should also be
used to determine if other non-specific inhibitory effects occur. Forskolin, a classic
agonist for PKA stimulation, was determined to be ineffective in activating ERK1/2
within the 5 minute exposure time used for these experiments. Consequently, it was not
used as a positive control for PMA activation ofERK and the data was not shown. (Figs.
11A&B, 12A&B)
Discussion
The regulation of the bone turnover cycle has long been a topic of discussion and query
within the scientific community. This cycle involves a series of highly regulated steps
that depend upon the interactions oftwo cell lineages, the hematopoietic osteoclastic
lineage and the mesenchymal osteoblastic lineage. Many different biological agents have
been implicated in allowing for the coupling of the resorption and deposition of bone by
these two cells. Due to the high concentrations of extracellular Calcium (Cae) found in
local sites of remodeling, Cae has been studied to determine its role in this process. If
Cae is a coupling agent these cells must be able to sense extracellular calcium by some
means. A calcium-sensing receptor (CAR) has been found on osteoblasts and other cells
within the body.
3+Quarles, et al., showed that high Cae and other CaR agonists, such as Gd e and
neomycin, stimulated DNA synthesis in MC3T3-E 1 cells in a dose-dependent manner.
Although Quarles’ investigations do not support the presence of a putative CaR
(homologous to parathyroid cells) on osteoblasts, his evidence does demonstrate the
existence of an osteoblastic receptor that produces physiologic changes in response to
elevated extracellular calcium. (Quarles, et al., 1997) Moreover, there are apparent
differences in signal transduction pathways activated by cations in osteoblasts compared
with the second messengers utilized by CaR in other cell systems. For example, CaR is
linked to PI-PLC activation leading to increases in IP3 levels and intracellular calcium
concentration, whereas cation simulation of osteoblasts leads to PKC activation via
alternative pathways that do not involve an increase in intracellular calcium. Though
cell-related differential coupling to various G proteins and the consequent utilization of
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different intracellular signaling cascades might account for some of these observations,
the dissimilar cation specificity and functional effects suggest that osteoblasts may not
express a receptor that is identical to CaR. (Quarles, et al., 1997)
There are other reports failing to show expression of the CaR in human peripheral
blood monocytes (Bomefalk, 1997) and human osteoblast-like SAOS-2 cells (Gunnet,
1997), these results were based on the single finding of negative results of RT-PCR using
CaR-specific primers, but not on the methods detecting CaR protein expression, such as
immunocytochemistry and Westem analysis. Yamaguchi, et al. (1998) found that
detection of CaR transcripts by RT-PCR or Nothem blot analysis in MC3T3-E1 cells
was, in general, more difficult than identification of receptor protein using
immunocytochemistry and Western analysis and the results should therefore be more
cautiously interpreted. Since the complete DNA sequence of the mouse CaR has not
been determined, Quarles, et al., (1997) performed RT-PCR ofmouse CaR with primers
designed from human CaR and were unable to amplify CaR-derived products at an
annealing temperature of 60C in MC3T3-E1 cells. However, this temperature might be
too high for effective priming of the mouse CaR in MC3T3-E 1 cells in view ofthe
species mismatch between primers and their DNA template as well as the probable lower
expression of CaR mRNA in the osteoblastic cells relative to those in the parathyroid and
kidney. Yamaguchi, et al. (1998), also failed to amplify any PCR products even with
mouse CaR-derived primers in MC3T3-E 1 cells when annealing temperatures above
50C were used and found that a temperature of47C was optimal for successful
amplification ofthe CaR-derived product by PCR. Moreover, they also found that
ordinary Taq DNA polymerase was relatively ineffective for amplifying CaR mRNA
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from MC3T3-E1 cells, and that only "hot start" PCR using a mixture of Taq/Pyrococcus
species GB-D DNA polymerases, which have proofreading activity, resulted in
successful amplification. Therefore, RT-PCR of the mouse CaR may require careful
selection of the experimental conditions that are ideal for PCR. In a study done by
Yamaguchi, et al. (1998), the possibility of amplifying CaR from genomic DNA was
totally eliminated because the primer pair was designed to span one intron of the CaR
gene. The primer pair amplified a product of the size expected for a CaR-derived
product, and no PCR product was amplified without RT. In the same study, Yamaguchi,
et al. (1998), were able to successfully detect CaR transcripts in MC3T3-E1 cells using
Northern blot analysis under moderately stringent hybridization and washing conditions,
utilizing a rat CaR-specific cRNA probe and 5 l-tg of poly(A+) RNA instead ofthe cDNA
probe and 2 g ofpoly(A+) RNA that was employed by Quarles, et al. (1997). The
principle bands observed by Yamaguchi, et al. (1998), in MC3T3-E1 cells were similar in
size to two minor bands observed on Northem analysis of mouse kidney performed on
poly(A+) under high stringency conditions. They also employed two different
stringencies with MC3T3-E 1 cells and mouse kidney cells because of the use of
heterologous (e.g., rat) probe and since the relative abundance of the CaR transcripts in
MC3T3-E1 cells are much lower than in mouse kidney. The use of high stringency
conditions for hybridization and washing would have greatly reduced the signal intensity
observed in the MC3T3-E1 cells relative to that in the kidney. A final possible
explanation for the disagreements about the CaR, although not probable, is variations in
the clones of MC3T3-E1 cells in which some clones show little or no expression of the
CaR at all. (Yamaguchi, et al., 1998)
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Although the exact nature of the Cae-sensing receptor remains unknown, the
results of this project suggest that the Gi-protein isoform is not involved in Cae-
stimulated activation of ERK1/2 in MC3T3-E1 osteoblasts due to pertussis toxin’s
inability to cause an effective inhibition of Cae stimulated ERK1/2 activation. Many
different isoforms of G-proteins exist and they all use various combinations of subunit
signal transducers. An ct-subunit, [-subunit, and ),-subunit exist. The ct-subunit, to date,
has 20 different known isoforms and often works independently of the [3 and , subunits.
Five isoforms of the 13-subunit and 6 isoforms of the /-subunit have been identified and
these usually work together as a single unit in a plethora of combinations. (Cascieri,
1996) Because of the multiple possible G-protein subunits involved, one cannot discount
G-proteins as a possible means by which Cae elicits a response.
It was also shown that the PMA-dependent PKC pathway is involved in the Cae-
stimulated ERK1/2 activation. However, as with many signaling molecules, multiple
isoforms ofPKC exist. PKC specific inhibitors, Go 6983 and GF109203X had no effect
on Cae-stimulated ERK1/2 activation. Hence, a conclusion could not be drawn regarding
whether or not PKC isoforms are directly involved in Cae-stimulated ERK1/2 activation
and more research should be done in this area.
PKA is another potential signaling molecule involved in ERK1/2 activation via a
Cae-sensing receptor. Our inability to determine whether PKI (a PKA inhibitor) was
actually inhibiting the PKA pathway, prevented a definitive conclusion from being drawn
regarding the extent to which PKA may be involved. Further studies should be done to
elucidate the possible involvement ofPKA in Cae-stimulated ERK1/2 activation.
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Continued research involving the exact mechanism and specific type of receptor
responsible for these cellular responses should be done because as we continue to
discover the exact pathways involved in these processes, the closer we come to being
able to manipulate them. Once manipulation can be achieved, treatment possibilities
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